Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jul 26;12(10):2200–2212. doi: 10.1158/1535-7163.MCT-13-0095

Figure 5.

Figure 5

Specific depletion of STAT3 reverses erlotinib resistance. A, STAT3 shRNA or control shRNA was transfected into HCC827 cells. Expression levels of STAT3, Bcl-XL and Bcl2 were analyzed by Western blot. B, HCC827 cells expressing STAT3 shRNA or control shRNA were treated with erlotinib (Erlo) for 48h. Cell growth was determined by SRB assays.